The HemOnc Pulse
What are the Controversies Surrounding MRD in Blood Cancers?
Apr 25, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss measurable residual disease (MRD) in blood cancers, highlighting controversies, implications of MRD negativity, harmonizing MRD thresholds, and testing MRD technology in trials. They explore the challenges in achieving and maintaining MRD negativity for long-term disease control, individualized approaches based on disease specifics, and the importance of overall survival benefits in chronic diseases like CLL.
40:59
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- MRD in blood cancers offers accurate response assessments but lacks clear guidelines for treatment decisions.
- Harmonizing MRD testing methods is essential to ensure consistent and reliable results for patient management.
Deep dives
Importance of MRD in Hematologic Malignancies
MRD, or measurable residual disease, is a critical concept in hematology, offering insight into disease detection beyond conventional methods such as imaging studies. The ability to detect minimal amounts of cancer cells directly in the bone marrow has revolutionized response assessments and treatment approaches in diseases like myeloma and CLL. While the technology signifies a significant advancement providing more accurate data, the challenge remains in determining how to act on this information to avoid over or under-treatment until clinical trials establish clear guidelines.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
